Glucocorticoid Use and Risk of Atrial Fibrillation or Flutter: A Population-Based, Case-Control Study

Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark.
Archives of internal medicine (Impact Factor: 17.33). 10/2009; 169(18):1677-83. DOI: 10.1001/archinternmed.2009.297
Source: PubMed


Glucocorticoid use is associated with increased risk of myocardial infarction, stroke, and heart failure, but data are limited on the risk of atrial fibrillation or flutter. We examined whether glucocorticoid use is associated with the risk of atrial fibrillation or flutter.
For this population-based, case-control study, we identified all patients with a first hospital diagnosis of atrial fibrillation or flutter from January 1, 1999, through December 31, 2005, in Northern Denmark (population, 1.7 million). For each case we selected 10 population controls matched by age and sex. We obtained data on glucocorticoid prescriptions within 60 days (current users) or longer before the index date (former users), comorbidity, and medications from medical databases. We used conditional logistic regression to compute odds ratios (ORs), controlling for potential confounders.
Among 20,221 patients with atrial fibrillation or flutter, 1288 (6.4%) were current glucocorticoid users and 2375 (11.7%) were former users. Among 202,130 population controls, 5245 (2.6%) were current glucocorticoid users and 19 940 (9.9%) were former users. Current glucocorticoid use was associated with an increased risk of atrial fibrillation or flutter compared with never use (adjusted OR, 1.92; 95% confidence interval [CI], 1.79-2.06). Among new glucocorticoid users, the adjusted OR was 3.62 (95% CI, 3.11-4.22) and among long-term users it was 1.66 (95% CI, 1.53-1.80). The increased risk remained robust in patients with and without pulmonary and cardiovascular diseases. Former glucocorticoid use was not associated with increased risk (adjusted OR, 1.00; 95% CI, 0.96-1.06).
Current glucocorticoid use was associated with an almost 2-fold increased risk of atrial fibrillation or flutter.

Download full-text


Available from: Christian Fynbo Christiansen,
24 Reads
  • Source
    • "At present, it is not fully understood why individuals with arthritis may report higher likelihood of stroke. Rincón et al. [19] have speculated that a state of chronic inflammation may contribute to an elevated risk of stroke, whereas others have proposed that the pathway may be more related to atrial fibrillation and heart failure [20], either directly [21] or through long-term use of glucocorticoids [22] and NSAID medication [23]. These studies notwithstanding our analyses revealed an association with most of the traditional risk factors for stroke (e.g., hypertension, heart disease, and diabetes). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Arthritis is a chronic inflammatory condition commonly associated with mobility restriction and reduced activity. To date, the extent to which arthritis is an independent risk factor for stroke is unclear, and important, in light of an aging population. The purpose of this study was to (i) quantify the cross-sectional association between stroke and arthritis and (ii) to determine whether the relationship differed in physically active and inactivemiddle-aged and older adults. Data was derived from the 2010 Canadian Community Health Survey (N = 47 188; ≥30 y). Multivariable logistic regression was used to estimate the association between arthritis and stroke in models adjusted for age, physical activity (PA), and demographic factors. Overall, individuals with arthritis were 4 times more likely to report a history of stroke (OR = 3.8, 95% CI = 3.06-4.68), whereas those who were engaged in at least moderate PA (≥ 1.5 kcal/kg/day) were less than half as likely (0.45, 0.92-0.62). This effect was moderated by age, as younger (30-65 y: 3.27, 2.22-4.83) but not older adults (>65 y: 1.04, 0.8-1.35) with arthritis had elevated odds of stroke. Both physical inactivity and arthritis are associated with higher odds of stroke, effects of which are the strongest amongst 30-65 year olds.
    Stroke Research and Treatment 04/2014; 2014:651921. DOI:10.1155/2014/651921
  • Source
    • "We used the same methodology as above, further adjusting for medication use as a marker of underlying disease associated with AF/flutter prescribed in the year before index date (cardiovascular, respiratory, or antithyroid drugs, thyroid hormone replacement therapy, non-steroid inflammatory drugs or COX-2 inhibitors, vitamin K antagonists, and oral glucocorticoid drugs (Christiansen et al, 2009 for codes)). We also did an analysis excluding digoxin users, which are likely to represent prevalent AF/flutter, and another analysis excluding oral bisphosphonate users. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is conflicting evidence regarding bisphosphonates and atrial fibrillation (AF) risk in osteoporosis patients. However, bisphosphonates are used in much higher doses in treatment of bone metastasis and hypercalcemia, but little is known about the AF risk in cancer patients. We conducted a nationwide population-based cohort study using Danish databases. All cancer patients exposed to intravenous bisphosphonates during 2000-2008 were matched with two non-exposed cancer patients by cancer type, distant metastasis presence at diagnosis, age, and gender. We used Cox proportional hazard regression to estimate hazards ratios (HRs) of AF/flutter adjusting for important confounding factors. Of the 3981 cancer patients exposed to intravenous bisphosponates, 128 (3.2%) developed AF/flutter. This condition occurred in 192 (2.4%) of the 7906 non-exposed cancer patients, corresponding to an adjusted HR of 1.7 (95% CI: 1.2-2.4). Intravenous bisphosphonates may increase AF/flutter risk in cancer patients.
    British Journal of Cancer 08/2011; 105(7):881-3. DOI:10.1038/bjc.2011.338 · 4.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bisphosphonates are the most commonly used treatment for osteoporosis and have proven efficacy in the reduction of vertebral and nonvertebral fractures. Recently, concerns have been raised about a possible association between bisphosphonate therapy and atrial fibrillation (AF) following the report of a significant increase in risk of serious AF in women treated with zoledronic acid in the HORIZON study. Subsequent studies have produced conflicting results but have not excluded the possibility of such an association. Currently there is no direct evidence that bisphosphonates exert either acute or chronic effects on cardiac electrophysiology. Nevertheless, altered intracellular electrolyte homeostasis and proinflammatory, profibrotic, and antiangiogenic effects provide potential mechanisms by which atrial conduction could be affected in patients treated with bisphosphonates. In studies in which an increase in risk of AF has been identified, there is no evidence that this translates into increased mortality or increased risk of stroke, and the risk-benefit balance of bisphosphonate therapy in patients with osteoporosis and other forms of metabolic bone disease remains strongly positive.
    Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 01/2010; 25(1):2-10. DOI:10.1359/jbmr.091201 · 6.83 Impact Factor
Show more